Differentiating human trophoblast stem cells in mammalian straitum
View Patent ↗Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies.
1. A method of differentiating an isolated human trophoblast stem cell into a neuron, the method comprising:
administering said human trophoblast stem cell to the striatum region of the brain of a mammal, wherein said human trophoblast stem cell differentiates into a neuron, and
wherein said human trophoblast stem cell expresses transcripts for SSEA-1, SSEA-3, SSEA-4, and Oct4, and is isolated from trophoblast tissue.
2. The method of claim 1 , wherein said neuron is a dopaminergic neuron.
3. The method of claim 1 , wherein said stem cell is pre-induced with an all trans-retinoic acid prior to said administering.
4. The method of claim 1 , wherein said stem cell is not pre-induced with an induction drug prior to said administering.
5. The method of claim 1 , wherein said brain of said mammal is damaged or suffered neuronal loss, prior to said administering.
6. The method of claim 5 , wherein said damage is to a dopaminergic neuron.
7. The method of claim 5 , wherein said neuronal loss is to a dopaminergic neuron.
8. The method of claim 1 , wherein said stem cell is transfected with an expression vector.
9. The method of claim 1 wherein the stem cell, after being administered to said mammal, extends processes into the substantia nigra pars compacta (SNc) region of said brain of said mammal.
10. The method of claim 1 further comprises administering to the mammal an effective amount of a therapeutic compound.
11. The method of claim 10 , wherein the therapeutic compound is a drug, a chemical, or an antibody.
12. The method of claim 1 further comprises administering to the mammal an effective amount of a compound that modulates bFGF, Oct 4, FGFR-2 or FGF4 expression, in said stem cell.
13. The method of claim 12 , wherein the compound is an inhibitor of bFGF, Oct 4, FGFR-2 or FGF4.
14. The method of claim 1 , wherein the mammal is a human.
15. The method of claim 1 , wherein the administering is via injection, transplantation, or surgical operation.